Charles river opens new biomedical diagnostic facility
Wilmington, mass.--(business wire)--charles river laboratories, inc. (nyse: crl) today announced the opening of its new biomedical diagnostic testing facility in wilmington, massachusetts. the state-of-the-art, 60,000-square-foot r&d services facility expands the company’s diagnostic capabilities for research model health monitoring, clinical chemistry, hematology, biomarker assay development and immunoassay services. the new facility offers high-functioning, controlled environments, building monitoring and mechanical systems redundancy, as well as energy reduction through occupancy sensor-driven air distribution and lighting. “our new facility provides charles river with additional capacity for growth, as well as the capability to utilize innovative technology platforms to advance the high-quality r&d services we provide our biopharmaceutical and academic clients,” said james c. foster, chairman, president and chief executive officer. “the opening of this building also demonstrates our commitment to investing in growth businesses and our employees, as well as doing business in the commonwealth of massachusetts.” charles river is one of the largest global preclinical contract research organizations, or cros, with approximately 1,000 employees in massachusetts and approximately 7,100 employees globally. in the 65 years since its founding in 1947, charles river has expanded from a provider of high-quality research models to a full-service, early-stage cro with a broad portfolio of essential products and services that support our clients’ drug discovery and development efforts. about charles river accelerating drug development. exactly. charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. to learn more about our unique portfolio and breadth of services, visit www.criver.com.
CRL Ratings Summary
CRL Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission